Inclusion Criteria:

          1. Age ≥ 18 years of age

          2. Histologically proven squamous cell carcinoma, adenocarcinoma or undifferentiated
             carcinoma of the esophagus or GE junction.

          3. Surgically resectable (T1-3 Nx by endoscopic ultrasound). Excluded are:

               1. Very early stage tumors (T1N0)

               2. Cervical esophageal tumors

               3. Tumors invading the tracheobronchial tree or associated with tracheoesophageal
                  fistula

               4. Any evidence of distant metastases (as determined by endoscopic ultrasound (EUS)
                  or CT/PET)

               5. Cervical, supraclavicular, or other nodal disease that is either not included in
                  the radiation field or is not able to be resected at the time of esophagectomy

          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          5. Adequate hematological, renal, and hepatic parameters defined as follows:

               1. Absolute Neutrophil Count (ANC) ≥1.5 × 109/L in absence of growth factor support

               2. Platelet count ≥150 × 109/L

               3. Hemoglobin >9 g/dL

               4. Serum creatinine ≤1.5 mg/dL, or calculated (using the formula of Cockcroft and
                  Gault) or measured creatinine clearance ≥30 mL/min

               5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x upper
                  limit of normal (ULN)

               6. Total bilirubin ≤1.5x ULN

          6. Women of child bearing potential (WOCBP) must have a negative serum pregnancy test
             within the 7 days prior to investigational product administration and a negative urine
             pregnancy test within the 3 days prior to the first investigational product
             administration, or a negative serum pregnancy test within the 3 days prior to the
             first investigational product administration

          7. WOCBP and male subjects who are sexually active with WOCBP must agree to use 2 highly
             effective methods of contraception (including a physical barrier) during the study and
             for 30 days following the last dose of investigational product

          8. Ability to understand a written informed consent document, and the willingness to sign
             it

        Exclusion Criteria:

          1. Any history of or current hematologic malignancy

          2. History of a second primary cancer is allowed in the event the cancer is curatively
             resected and there is no evidence of recurrence/metastatic disease x 1 year. Subjects
             who have a history of cervical or breast carcinoma in situ, localized prostate cancer,
             adequately treated basal cell or squamous cell carcinoma of the skin, or superficial
             bladder tumors [Ta, Tis & T1] are also allowed

          3. Major surgery within 4 weeks of first dose of investigational product

          4. Prior or concurrent treatment with any anticancer agent for the same cancer diagnosis

          5. Prior exposure to any immuno-oncology agents, including CD40/PD-1/PD-L1/CTLA-4
             inhibitors (if any ambiguity, should be discussed with study principal investigator)

          6. History of bone marrow transplantation

          7. Uncontrolled diabetes or hypertension

          8. History of autoimmune disorders with the exception of vitiligo or autoimmune thyroid
             disorders

          9. Chronic steroid dependency (prednisone equivalent > 10 mg/day). Any steroid use should
             be discontinued at least 2 weeks prior to initiation of study treatment.

         10. History of sensitivity or allergy to monoclonal antibodies (mAbs) or immunoglobulin G
             (IgG)

         11. History of severe hypersensitivity reaction to Cremophor EL.

         12. Pre-existing > grade 2 peripheral sensory neuropathy.

         13. Congestive heart failure (New York Heart Association Class III to IV), symptomatic
             ischemia, conduction abnormalities uncontrolled by conventional intervention, or
             myocardial infarction within 6 months before first dose

         14. History of any arterial thromboembolic event within 3 months prior to first dose of
             investigational product

         15. Active coagulopathy

         16. Active known clinically serious infections (> Grade 2 National Cancer Institute (NCI)-
             CTCAE version 4.03)

         17. Known human immunodeficiency virus (HIV) infection

         18. Subjects of reproductive potential who do not use effective methods of birth control

         19. Pregnant or actively breastfeeding women

         20. Any clinically significant psychiatric, social, or medical condition that, in the
             opinion of the Investigator, could increase subject's risk, interfere with protocol
             adherence, or affect a subject's ability to give informed consent.